Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1291583 in Healthy Subjects
NCT03868540Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in bronchiectasis comparing BI 1291583 with Placebo (2 arms). Primary endpoint: Percentage of participants with drug-related adverse events up to 49 days. Started Mar 2019; status: terminated.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT03868540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03868540.